Ardelyx Taps Correvio’s Justin Renz as Its Chief Financial Officer

Justin Renz has joined Ardelyx (NASDAQ: [[ticker:ARDX]]) as chief financial officer. Renz most recently held the same role at Vancouver, BC-based Correvio Pharma, which was acquired last month by the UK company Advanz Pharma for about $76 million. His prior experience includes management roles at Karyopharm Therapeutics (NASDAQ: [[ticker:KPTI]]) and Zalicus (formerly CombinatoRx).

Fremont, CA-based Ardelyx, which is developing treatments for patients with kidney and cardiovascular diseases, this year plans to request FDA review of tenapanor, its lead drug candidate, as a treatment for chronic kidney disease patients on dialysis to better control their serum phosphorus levels. Last year the FDA approved tenapanor (Ibsrela) for the treatment of irritable bowel syndrome with constipation.

Author: Sarah de Crescenzo

Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register. She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine. View all posts by Sarah de Crescenzo